Adamas Releases Final Results of Two-Year Phase 3 Trial of GOCOVRI® for Dyskinesia

(February 11, 2020) The longest-running amantadine study to date of the only FDA-approved medicine for dyskinesia indicates GOCOVRI may help people with PD who are struggling to manage levodopa-related motor complications. Read more.

Follow Us Follow us on TwitterFollow us on FacebookInstagram

Sign Up for Email Alerts

By providing your email you agree to receive periodic emails from The Parkinson Alliance.

Please tell us more about yourself:

This month is? (Anti-Spam)

Contact UsTerms Of UsePrivacy Policy

The Parkinson Alliance is a nonprofit, tax-exempt charitable organization under section 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law. Copyright © 2020 The Parkinson Alliance. All rights reserved.